Biopharmaceutical company Nimbus Discovery has secured $24 million of Series A venture financing. Atlas Venture, SR One and Lilly Ventures co-led the investment. The company’s existing investor Bill Gates also participated.
The company intends to use the funds to accelerate existing programs, targeting IRAK4 and ACC, in inflammation, cancer and metabolic disease. Kent Gossett, managing director and partner at SR One, and Steve Hall, venture partner at Lilly Ventures, have joined the Nimbus board of directors, in connection with the financing.
Click here for the release from Business Wire.